Baxter may jettison vaccine unit

Baxter (BAX) hires Goldman Sachs to help find a buyer for its $300M vaccines business that includes vaccines for meningitis C and tick-borne encephalitis.

The company's move is another example of a large healthcare firm trying to divest non-core assets.

From other sites
Comments (1)
  • Eweball
    , contributor
    Comments (69) | Send Message
    Wall Street seems to like the idea judging from the 2.3% jump in the stock price on Wednesday. Hopefully the company won't indicate they'll use the money to buy back their own stock.
    26 Mar 2014, 01:49 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs